Sai Life Sciences Ltd Q2 FY2026 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/bhm9e2sryb5wu7winn586ubb.pdf

Key Takeaways


Financial Performance

Krishna Kanumuri: "Our whole strategy is to be a much bigger piece of the overall pie for our customers than just being a product service provider where a lot of other companies are focusing on at this point."

Capacity Expansion & Capex

Krishna Kanumuri: "We don't build for that once-in-a-lifetime opportunity. We build more for a question of higher certainty of filling the pipeline rather than the blockbuster to come in."

New Modalities & Technology Platforms

Krishna Kanumuri: "All I will say is that right now, anybody today tells you that I have a strategy for ADCs, I have a defined strategy of peptide, I have defined strategy for oligonucleotides you can park it, because it's changing so quickly because the technology is shifting quickly."

Demand Environment & End-Market Dynamics

Krishna Kanumuri: "The best thing for you is to ask a pharma guy if he can give you a pipeline. He'll answer. There will be no way. We're basically dealing with a very, what do you call, unplanned business to a great extent."

Strategic Initiatives & New Entries


Guidance & Commitments

CommitmentSpecificsTimeline
Revenue growth15%-20% revenue growthOver 3-5 year period
EBITDA margin28%-30% EBITDANo specific timeline; continued focus
Capacity expansionScale total installed capacity from ~700 KL to 1,150 KLBy end of FY27
FY26 capexINR 700 crores totalFull year FY26
Oligonucleotide validationPhosphoramidite process validation for commercial molecule15-18 months before becoming commercial
ADC announcementWill announce once more data is availableNo specific date
FY27 capex guidanceWill provide later; plan is evolvingNo specific date

Key Metrics

MetricQ2 FY26
Total revenue (H1 FY26)₹1,034 cr, +53% YoY over ₹675 cr in H1 FY25
CDMO revenue (H1 FY26)₹667 cr, 64% of total revenue, +72% YoY
CRO revenue (H1 FY26)₹367 cr, 36% of total revenue, +28% YoY
EBITDA (H1 FY26)₹281 cr, +101% YoY over ₹140 cr in H1 FY25
EBITDA margin (H1 FY26)27%, improved 650 bps YoY
PAT (H1 FY26)₹144 cr
Capex (H1 FY26)₹248 cr, against full-year plan of ₹700 cr
Revenue growth guidance15%–20% over a 3–5 year period
Total installed capacity~700 KL, scaling to 1,150 KL by end of FY27
Late-stage pipeline additions3 products moved to late-stage during the quarter
Customer audits (trailing 12 months)35 customer audits, 3 regulatory audits, zero data integrity deviations, zero critical observations
Animal health partnerships3 of the top 5 global animal health companies partnered
Oligonucleotide validation timeline15–18 months before commercial for the molecule under validation
Consulting fees (one-off in other expenses)Double-digit crores in Q2 FY26